Effect of cerebrolysin on motor function restoration during medical rehabilitation
https://doi.org/10.14412/2074-2711-2016-2-80-86
Abstract
Ischemic stroke (IS) is characterized by high prevalence, mortality, and disability rates. Therapy aimed to correct one biochemical or molecular stage of ischemic cell injury fails to treat stroke, suggesting that it is necessary to study multimodality therapy affecting several related pathophysiological components.
The paper gives the January 2016 results of the randomized placebo-controlled multicenter study CARS that demonstrates the positive effect of cerebrolysin versus placebo according to the primary efficiency criterion, the Action Research Arm Test (ARAT) scale, and total outcome 90 days after disease onset. The investigation enrolled mainly patients with moderate or severe IS (the mean National Institutes of Health Stroke Scale score was 9 at baseline).
The specific features of the CARS study versus those of other clinical trials of neuroprotectors were the initial planning of narrower end criteria of efficiency (arm motor function recovery whereas the major goal of many investigations was to reduce mortality rates), as well as a standardized rehabilitation program in both treatment groups. Such investigations did not previously take into account the nature and volume of rehabilitation measures although the latter may have a substantial impact on the outcome of stroke.
The CARS study is the first among the previously conducted clinical trials of neuroprotectors, which has attained the primary objective (to restore motor function), which opens up fresh opportunities for the medical support of rehabilitation measures in patients with IS.
About the Authors
M. A. Kustova
Research Institute of Cerebrovascular Pathology and Stroke, N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia, Moscow
Russian Federation
1, Ostrovityanov St., Moscow 117997
Russian Federation
1, Ostrovityanov St., Moscow 117997
A. P. Tolmachev
Research Institute of Cerebrovascular Pathology and Stroke, N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia, Moscow
Russian Federation
1, Ostrovityanov St., Moscow 117997
Russian Federation
1, Ostrovityanov St., Moscow 117997
N. A. Shamalov
Research Institute of Cerebrovascular Pathology and Stroke, N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia, Moscow
Russian Federation
1, Ostrovityanov St., Moscow 117997
Russian Federation
1, Ostrovityanov St., Moscow 117997
References
1. Murray CJ, Lopez AD. Measuring the global burden of disease. N Engl J Med. 2013 Aug 1;369(5):448-57. doi: 10.1056/NEJMra1201534.
2. Powers WJ, Derdeyn CP, Biller J, et al., on behalf of the American Heart Association Stroke Council. 2015 AHA/ASA Focused Update of the 2013 Guidelines for the Early Management of Patients With Acute Ischemic Stroke Regarding Endovascular Treatment. A Guideline for Healthcare Professionals from the American Heart Association/American Stroke Association. Stroke. 2015; 46:3020-3035. Stroke. 2015;46:3020-3035 Published online before print June 29, 2015, doi: 10.1161/ STR.0000000000000074
3. Saver JL, Smith EE, Fonarow GC, et al. GWTG- Stroke Steering Committee and Investigators. The «golden hour» and acute brain ischemia: presenting features and lytic therapy in >30,000 patients arriving within 60 minutes of stroke onset. Stroke. 2010 Jul;41(7):1431-9. doi: 10.1161/ STROKEAHA.110.583815. Epub 2010 Jun 3.
4. Zahuranec DB, Majersik JJ. Percentage of acute stroke patients eligible for endovascular treatment. Neurology. 2012 Sep 25;79(13 Suppl 1):S22-5.
5. Шамалов НА. Проблемы и перспективы реперфузионной терапии при ишемическом инсульте в России. Фарматека. 2015;302(9):14-9. [Shamalov NA. Problems and prospects of reperfusion therapy in ischemic stroke in Russia. Farmateka. 2015;302(9):14-9. (In Russ.)].
6. O’Collins VE, Macleod MR, Donnan GA, et al. 1,026 experimental treatments in acute stroke. Ann Neurol. 2006 Mar;59(3):467-77. doi: 10.1002/ana.20741
7. Kaur H, Prakash A, Medhi B. Drug therapy in stroke: from preclinical to clinical studies. Pharmacology. 2013;92(5-6):324-34. doi: 10.1159/000356320. Epub 2013 Dec 12.
8. Xu SY, Pan SY. The failure of animal models of neuroprotection in acute ischemic stroke to translate to clinical efficacy. Med Sci Monit Basic Res. 2013 Jan 28;19:37-45.
9. Tymianski M. Novel approaches to neuroprotection trials in acute ischemic stroke. Stroke. 2013 Oct;44(10):2942-50. doi: 10.1161/ STROKEAHA.113.000731. Epub 2013 Sep 10.
10. Hossmann KA. The two pathophysiologies of focal brain ischemia: implications for translational stroke research. J Cereb Blood Flow Metab. 2012 Jul;32(7):1310-6. doi: 10.1038/jcbfm.2011.186. Epub 2012 Jan 11.
11. Masliah E, Diez-Tejedor E. The pharmacology of neurotrophic treatment with Cerebrolysin: brain protection and repair to counteract pathologies of acute and chronic neurological disorders. Drugs Today (Barc). 2012 Apr;48 Suppl A:3-24. doi: 10.1358/ dot.2012.48(Suppl.A).1739716.
12. Hartbauer M, Hutter-Paier B, Skofitsch G, Windisch M. Antiapoptotic effects of the peptidergic drug cerebrolysin on primary cultures of embryonic chick cortical neurons. J Neural Transm (Vienna). 2001;108(4):459-73.
13. Zhang L, Chopp M, Meier DH, et al. Sonic hedgehog signaling pathway mediates cerebrolysin-improved neurological function after stroke. Stroke. 2013 Jul;44(7):1965-72. doi: 10.1161/STROKEAHA.111.000831. Epub 2013 May 21.
14. Gutmann B, Hutter-Paier B, Skofitsch G, et al. In vitro models of brain ischemia: the peptidergic drug cerebrolysin protects cultured chick cortical neurons from cell death. Neurotox Res. 2002 Feb;4(1):59-65. doi: 10.1080/ 10298420290007637.
15. Darsalia V, Heldmann U, Lindvall O, Kokaia Z. Stroke-induced neurogenesis in aged brain. Stroke. 2005 Aug;36(8):1790-5. Epub 2005 Jul 7. doi: 10.1161/01. STR.0000173151.36031.be.
16. Скворцова ВИ, Стаховская ЛВ, Губский ЛВ и др. Рандомизированное двойное слепое плацебоконтролируемое иссле- дование безопасности и эффективности церебролизина для лечения острого ишемиче- ского инсульта. Журнал неврологии и психиатрии им. С.С. Корсакова (Прил. Инсульт). 2004;(S11):51-5. [Skvortsova VI, Stakhovskaya LV, Gubskii LV, et al. A randomized, double-blind, placebocontrolled trial of safety and efficacy of Cerebrolysin for treating acute ischaemic stroke. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova (Suppl. Stroke). 2004;(S11):51-5. (In Russ.)].
17. Ladurner G, Kalvach P, Moessler H; Cerebrolysin Study Group. Neuroprotective treatment with cerebrolysin in patients with acute stroke: a randomised controlled trial. J Neural Transm (Vienna). 2005 Mar;112(3):415-28. Epub 2004 Dec 7. doi: 10.1007/s00702-004-0248-2.
18. Ziganshina LE, Abakumova T, Kuchaeva A. Cerebrolysin for acute ischaemic stroke. Cochrane Database Syst Rev. 2010 Apr 14;(4): CD007026. doi: 10.1002/14651858. CD007026.pub2.
19. Lang W, Stadler CH, Poljakovic Z, Fleet D; Lyse Study Group. A prospective, randomized, placebo-controlled, double-blind trial about safety and efficacy of combined treatment with alteplase (rt-PA) and Cerebrolysin in acute ischaemic hemispheric stroke. Int J Stroke. 2013 Feb;8(2):95-104. doi: 10.1111/j.1747- 4949.2012.00901.x. Epub 2012 Sep 26.
20. Heiss WD, Brainin M, Bornstein NM, et al; Cerebrolysin Acute Stroke Treatment in Asia (CASTA) Investigators. Cerebrolysin in patients with acute ischemic stroke in Asia: results of a double-blind, placebo-controlled randomized trial. Stroke. 2012 Mar;43(3):630-6. doi: 10.1161/STROKEAHA.111.628537. Epub 2012 Jan 26.
21. Muresanu DF, Heiss WD, Hoemberg V, et al. Cerebrolysin and Recovery After Stroke (CARS). A Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial. Stroke. 2016 Jan;47(1):151-9. doi: 10.1161/STROKEAHA.115.009416. Epub 2015 Nov 12.
22. Lyle RC. A performance test for assessment of upper limb function in physical rehabilitation treatment and research. Int J Rehabil Res. 1981;4(4):483-92. doi: 10.1097/ 00004356-198112000-00001.
23. Posteraro L, Formis A, Grassi E, et al. Quality of life and aphasia. Multicentric standardization of a questionnaire. Eura Medicophys. 2006 Sep;42(3):227-30.
24. Goodglass H, Kaplan E. The Assessment of Aphasia and Related Disorders. 2nd ed. Philadelphia, PA: Lea & Febiger; 1983.
Review
For citations:
Kustova M.A., Tolmachev A.P., Shamalov N.A. Effect of cerebrolysin on motor function restoration during medical rehabilitation. Neurology, Neuropsychiatry, Psychosomatics. 2016;8(2):80-86. (In Russ.) https://doi.org/10.14412/2074-2711-2016-2-80-86
Views: 682
Email this article 